Ernexa Therapeutics (NASDAQ:ERNA) Raised to Hold at Wall Street Zen

Ernexa Therapeutics (NASDAQ:ERNA) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Several other research analysts also recently issued reports on ERNA. Zacks Research upgraded shares of Ernexa Therapeutics to a “hold” rating in a research report on Monday, May 11th. Brookline Capital Markets began coverage on shares of Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $30.00.

Ernexa Therapeutics Stock Performance

Ernexa Therapeutics stock opened at $6.97 on Friday. The firm has a market cap of $8.15 million, a P/E ratio of -0.27 and a beta of 2.49. The business’s fifty day moving average is $7.73 and its two-hundred day moving average is $14.41. Ernexa Therapeutics has a 52 week low of $3.18 and a 52 week high of $71.50.

Ernexa Therapeutics (NASDAQ:ERNA) last announced its earnings results on Monday, May 11th. The company reported ($6.95) EPS for the quarter, missing the consensus estimate of ($1.95) by ($5.00). On average, equities research analysts predict that Ernexa Therapeutics will post -18.02 earnings per share for the current year.

Institutional Investors Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent SEC filing. 70.55% of the stock is currently owned by hedge funds and other institutional investors.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.